The paediatric influenza treatment market is projected to grow from USD 641.1 USD million in 2025 to USD 904.3 USD million by 2035, at a CAGR of 3.5%. Neuraminidase Inhibitors will dominate with a 54.3% market share, while hospitals will lead the end user segment with a 63.5% share.